International Journal of Cancer · 2002 · 33 citations · 27 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyVaccinologyAntitumor T Cell ResponsesCancer ImmunotherapyCancer VaccinesTumor AntigensTumor-associated AntigensVaccine PlatformsAdaptive Antitumor ImmunityAntitumor Immune ActivationCancer Vaccine ImmunologyT-cell EpitopesTumor Antigen VaccinesTumor Antigen-based ImmunotherapyTumor ImmunogenicityTumor-associated Antigen Vaccines
The efficacy of phage display particles expressing tumor antigen P1A35-43 in inducing protective and therapeutic anti-tumor immune responses were studied. A protective immune response against a lethal progressive P815 mastocytoma tumor cell challenge was established after subcutaneous injection of phage display particles. Furthermore, the vaccine suppressed growth of pre-existing tumors. Immunization with the hybrid phage particles elicited P1A(35-43) specific CTL responses and a Th1-dominated immune response with phage particle-specific secretion of IFN-gamma but not IL-4. Our results indicate that phage display particles might be a useful vaccine form for tumor-associated antigen epitopes in tumor immunotherapy.
27
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Frank O. Nestlé, Selma Alijagic, Michel Gilliet et al. · Nature Medicine · 1998 · 2.9K citations
Medicine, Immunology, Oncology +14
Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells
Frank J. Hsu, Claudia Benike, Francesco Fagnoni et al. · Nature Medicine · 1996 · 1.8K citations
Medicine, Immunology, Oncology +16
Identification of a Peptide Recognized by Five Melanoma-Specific Human Cytotoxic T Cell Lines
Andrea L. Cox, Jonathan Skipper, Ye Chen et al. · Science · 1994 · 834 citations
Life Sciences, Immunology, Oncology +17